[HTML][HTML] Sofosbuvir treatment and hepatitis C virus infection
M Nakamura, T Kanda, Y Haga, R Sasaki… - World journal of …, 2016 - ncbi.nlm.nih.gov
Hepatitis C virus (HCV) infection is a serious problem worldwide. The use of interferon-
based therapy has made HCV eradication challenging. The recent appearance of direct …
based therapy has made HCV eradication challenging. The recent appearance of direct …
[HTML][HTML] Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A …
S Iqbal, MH Yousuf, MI Yousaf - World journal of gastroenterology, 2017 - ncbi.nlm.nih.gov
AIM To prospectively evaluate the efficacy of sofobuvir (SOF) in hepatitis C patients infected
with hepatitis C virus (HCV) genotype 3 in Pakistan. METHODS The present study was …
with hepatitis C virus (HCV) genotype 3 in Pakistan. METHODS The present study was …
[HTML][HTML] Real-world experiences with a direct-acting antiviral agent for patients with hepatitis C virus infection
V Louie, NL Latt, D Gharibian, A Sahota… - The Permanente …, 2017 - ncbi.nlm.nih.gov
Methods A retrospective cohort study was conducted at Kaiser Permanente Southern
California involving patients with hepatitis C virus who received sofosbuvir treatment …
California involving patients with hepatitis C virus who received sofosbuvir treatment …
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection
MS Sulkowski, JJ Feld, E Lawitz… - Journal of viral …, 2018 - Wiley Online Library
The phase 2, open‐label ACCORDION (ClinicalTrials. gov: NCT 02349048) study
investigated the efficacy, safety and pharmacokinetics of a 6‐or 8‐week regimen of …
investigated the efficacy, safety and pharmacokinetics of a 6‐or 8‐week regimen of …
Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line
CS Librelotto, APDE Souza… - Anais da Academia …, 2021 - SciELO Brasil
Direct-acting antivirals have revolutionized the treatment of chronic hepatitis C. Sofosbuvir
and simeprevir are prescribed worldwide. However, there is a scarcity of information …
and simeprevir are prescribed worldwide. However, there is a scarcity of information …
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C
R D'Ambrosio, A Aghemo… - Expert Opinion on Drug …, 2015 - Taylor & Francis
Introduction: IFN-free regimens with direct antiviral agents (DAAs) against hepatitis C virus
(HCV) are likely to greatly expand patients' access and response to hepatitis C therapy …
(HCV) are likely to greatly expand patients' access and response to hepatitis C therapy …
High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV‐infected patients treated with sofosbuvir‐containing …
PV Perumalswami, N Patel, K Bichoupan… - Journal of viral …, 2016 - Wiley Online Library
To conduct surveillance and determine the safety profile of new hepatitis C virus treatments
in real‐world clinical practice. Hepatic decompensation and other serious adverse events …
in real‐world clinical practice. Hepatic decompensation and other serious adverse events …
[HTML][HTML] Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
LO Gomes, MR Teixeira, JA Rosa, AA Feltrin… - Revista do Instituto de …, 2018 - SciELO Brasil
In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were
introduced in the Brazilian health system for treatment of chronic hepatitis C, after their …
introduced in the Brazilian health system for treatment of chronic hepatitis C, after their …
Sofosbuvir induced leucocytoclasic vasculitis: a case report
E Campione, A Dattola, M Di Prete, D Di Paolo… - BMC dermatology, 2019 - Springer
Background We describe a case of leucocytoclasic vasculitis induced by Sofosbuvir and its
disappearence after the end of the therapy. The hepatitis C virus, firstly described in 1989, is …
disappearence after the end of the therapy. The hepatitis C virus, firstly described in 1989, is …
Retreatment of Egyptian chronic hepatitis C patients not responding to pegylated interferon and ribavirin dual therapy
M Aboushady, A Alwassief, M Abdelrazik… - Journal of Interferon & …, 2019 - liebertpub.com
In the current study, we aimed to assess the efficacy of different Sofosbuvir (SOF)-based
antiviral regimens available in Egypt in the treatment of Pegylated interferon/Ribavirin (PEG …
antiviral regimens available in Egypt in the treatment of Pegylated interferon/Ribavirin (PEG …